included 53 ICC patients who received PD-1 inhibitor combined with lenvatinib and Gemox chemotherapy for a retrospective study, and all patients experienced grade 3 or 4 adverse events, including fatigue and bone marrow suppression (20). This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.